Rilzabrutinib granted FDA Fast Track Designation for treatment of immune thrombocytopenia

Phase 3 trial initiated to evaluate rilzabrutinib, the potential first BTK inhibitor (Brutons tyrosine kinase inhibitor) for the treatment of immune thrombocytopenia